GlobeNewsWire
13 Apr 2026, 22:00 UTC · 23w ago
Verdict
Headline takes no side. We score AIM −0.40 across three claims — moderately bearish.
−0.40moderately bearish
More negative than 70% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
AIM ImmunoTech's audited financial statements for the fiscal year ended December 31, 2025, include a going concern emphasis of matter from its auditor.
So whatA going concern warning is a severe red flag indicating the company may not have sufficient liquidity to survive the next 12 months.
More negative than 99% of claims this week
The company expects to release the next update on the DURIPANC Phase 2 clinical study in June 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 66% of claims this week
Management expresses confidence in its ability to raise further funds based on the development of its lead drug, Ampligen.
More positive than 44% of claims this week
Which stocks this story touches
More negative than 70% of ticker scores this week
The company received a 'going concern' emphasis of matter in its audit report, indicating financial instability, despite positive clinical trial progress.
More positive than 55% of ticker scores this week
The company's drug Imfinzi is part of a study showing positive progress in treating metastatic pancreatic cancer.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
12h ago
−64.2%
Price agrees with the score
$0.1901 vs $0.5310 close before publication (Apr 13) · not market-adjusted
AIM chart →
